New use for an old drug: Metformin and atrial fibrillation

Lal and colleagues(1) reported an integrative approach—combining transcriptomics, iPSCs, and epidemiological evidence—to identify and repurpose metformin, a main first-line medication for the treatment of type 2 diabetes, as an effective risk reducer for atrial fibrillation.

Detalles Bibliográficos
Autores principales: Vinciguerra, Manlio, Olier, Ivan, Ortega-Martorell, Sandra, Lip, Gregory Y.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798075/
https://www.ncbi.nlm.nih.gov/pubmed/36543101
http://dx.doi.org/10.1016/j.xcrm.2022.100875
_version_ 1784860827554152448
author Vinciguerra, Manlio
Olier, Ivan
Ortega-Martorell, Sandra
Lip, Gregory Y.H.
author_facet Vinciguerra, Manlio
Olier, Ivan
Ortega-Martorell, Sandra
Lip, Gregory Y.H.
author_sort Vinciguerra, Manlio
collection PubMed
description Lal and colleagues(1) reported an integrative approach—combining transcriptomics, iPSCs, and epidemiological evidence—to identify and repurpose metformin, a main first-line medication for the treatment of type 2 diabetes, as an effective risk reducer for atrial fibrillation.
format Online
Article
Text
id pubmed-9798075
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97980752022-12-30 New use for an old drug: Metformin and atrial fibrillation Vinciguerra, Manlio Olier, Ivan Ortega-Martorell, Sandra Lip, Gregory Y.H. Cell Rep Med Preview Lal and colleagues(1) reported an integrative approach—combining transcriptomics, iPSCs, and epidemiological evidence—to identify and repurpose metformin, a main first-line medication for the treatment of type 2 diabetes, as an effective risk reducer for atrial fibrillation. Elsevier 2022-12-20 /pmc/articles/PMC9798075/ /pubmed/36543101 http://dx.doi.org/10.1016/j.xcrm.2022.100875 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Preview
Vinciguerra, Manlio
Olier, Ivan
Ortega-Martorell, Sandra
Lip, Gregory Y.H.
New use for an old drug: Metformin and atrial fibrillation
title New use for an old drug: Metformin and atrial fibrillation
title_full New use for an old drug: Metformin and atrial fibrillation
title_fullStr New use for an old drug: Metformin and atrial fibrillation
title_full_unstemmed New use for an old drug: Metformin and atrial fibrillation
title_short New use for an old drug: Metformin and atrial fibrillation
title_sort new use for an old drug: metformin and atrial fibrillation
topic Preview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798075/
https://www.ncbi.nlm.nih.gov/pubmed/36543101
http://dx.doi.org/10.1016/j.xcrm.2022.100875
work_keys_str_mv AT vinciguerramanlio newuseforanolddrugmetforminandatrialfibrillation
AT olierivan newuseforanolddrugmetforminandatrialfibrillation
AT ortegamartorellsandra newuseforanolddrugmetforminandatrialfibrillation
AT lipgregoryyh newuseforanolddrugmetforminandatrialfibrillation

Ejemplares similares